Original research
Neuroinflammation predicts disease progression in progressive supranuclear palsy
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Treatment for patients with progressive supranuclear palsy

    Malpetti et al. examined neuroinflammation in subcortical regions for predicting clinical progression in patients with progressive supranuclear palsy (PSP) (1). Principal component analysis (PCA) was applied for the analysis, and neuroinflammation and tau burden in the brainstem and cerebellum significantly correlated with the subsequent annual rate of change in the score of Progressive Supranuclear Palsy Rating Scale. Namely, PCA-derived [11C]PK11195 positron emission tomography (PET) markers of neuroinflammation and tau pathology significantly correlated with regional brain volume, but MRI volumes alone did not predict the clinical progression. I present some information with special reference to treatment strategies.

    As there are no modifiable lifestyle factors to suppress progression of PSP (2), keeping quality of life by symptom-controlling medications has been recommended. Morgan et al. reported that symptomatic medications, most often for parkinsonism and depression, were prescribed for 87% of patients with PSP, whose satisfaction was poor in most cases (3). Although there have been no effective neuroprotective therapies and/or disease-modifying agents for patients with tauopathies and synucleinopathies, Jabbari et al. recently identified that genetic variation at the leucine-rich repeat kinase 2 (LRRK2) locus was significantly associated with survival in PSP, which might be based on the effect of long noncoding RNA on LRRK2 expression (4). As LRRK2 is associ...

    Show More
    Conflict of Interest:
    None declared.